摘要:
We disclose a method for producing a mesodermal or a endodermal cell from a pluripotent stem cell, the method comprising activating a Wnt signalling pathway in the pluripotent stem cell. In some embodiments, the pluripotent stem cell is in a substantially 2 dimensional configuration, such as a monolayer, for at least a portion of the time when the Wnt signalling pathway is activated.
摘要:
The invention concerns the use of ligands of peripheral-type benzodiazepine receptors (PTBR) in the diagnosis and treatment of diseases involving cyst formation and in particular polycystic kidney disease. The invention further concerns the treatment of hypertension accompanying polycystic kidney disease, and pharmaceutical compositions and articles of manufacture for the treatment or diagnosis of the target disease or condition.
摘要:
Genes that are up- or down-regulated during differentiation provide important leverage by which to characterize and manipulate early-stage pluripotent stem cells. Over 35,000 unique transcripts have been amplified and sequenced from undifferentiated human embryonic stem cells, and three types of differentiated progeny. Statistical analysis of the assembled transcripts identified genes that alter expression levels as differentiation proceeds. The expression profile provides a marker system that has been used to identify particular culture components for maintaining the undifferentiated phenotype. The gene products can also be used to promote differentiation; to assess other relatively undifferentiated cells (such as cancer cells); to control gene expression; or to separate cells having desirable characteristics. Manipulation of particular genes can be used to forestall or focus the differentiation process, en route to producing a specialized homogenous cell population suitable for human therapy.
摘要:
The invention concerns new secreted factors encoded by clones P00184_D11 (SEQ ID NO: 1), P00185_D11 (SEQ ID NO: 3), P00188_D12 (SEQ ID NO: 5), P00188_E01 (SEQ ID NO: 7), P00194_G01 (SEQ ID NO: 9), P00194_G05 (SEQ ID NO: 11), P00194_H10 (SEQ ID NO: 13), P00199_D08 (SEQ ID NO: 15), P00203_D04 (SEQ ID NO: 17), P00203_E06 (SEQ ID NO: 19), P00209_F06 (SEQ ID NO: 21), P00219_D02 (SEQ ID NO: 23), P00219_F06 (SEQ ID NO: 25), P00220_H05 (SEQ ID NO: 27), P00222_G03 (SEQ ID NO: 29), P00225_C01 (SEQ ID NO: 32), P00227_D11 (SEQ ID NO: 34), P00228_F03 (SEQ ID NO: 36), P00233_H08 (SEQ ID NO: 38), P00235_G08 (SEQ ID NO: 40), P00239_C11 (SEQ ID NO: 42), P00240_E05 (SEQ ID NO: 45), P00247_A04 (SEQ ID NO: 50), P00248_B04 (SEQ ID NO: 52), P00249_F09 (SEQ ID NO: 54), P00258_A10 (SEQ ID NO: 56), P00262_C10 (SEQ ID NO: 58), P00269_H08 (SEQ ID NO: 62), P00628_H02 (SEQ ID NO: 66), P00629_C08 (SEQ ID NO: 68), P00641_G11 (SEQ ID NO: 71), P00648_E12 (SEQ ID NO: 73), P00697_C03 (SEQ ID NO: 75), and other mammalian homologues and variants of such factor, as well as polynucleotides encoding them. The invention further concerns methods and means for producing such factors and their use in the diagnosis and treatment of various cardiac, renal or inflammatory diseases.
摘要翻译:本发明涉及由克隆P00184_D11(SEQ ID NO:1),P00185_D11(SEQ ID NO:3),P00188_D12(SEQ ID NO:5),P00188_E01(SEQ ID NO:7),P00194_G01(SEQ ID NO: P00194_G05(SEQ ID NO:11),P00194_H10(SEQ ID NO:13),P00199_D08(SEQ ID NO:15),P00203_D04(SEQ ID NO:17),P00203_E06(SEQ ID NO:19),P00209_F06 (SEQ ID NO:21),P00219_D02(SEQ ID NO:23),P00219_F06(SEQ ID NO:25),P00220_H05(SEQ ID NO:27),P00222_G03(SEQ ID NO:29),P00225_C01 P00227_D11(SEQ ID NO:34),P00228_F03(SEQ ID NO:36),P00233_H08(SEQ ID NO:38),P00235_G08(SEQ ID NO:40),P00239_C11(SEQ ID NO:42),P00240_E05 P00248_A04(SEQ ID NO:50),P00248_B04(SEQ ID NO:52),P00249_F09(SEQ ID NO:54),P00258_A10(SEQ ID NO:56),P00262_C10(SEQ ID NO: ),P00269_H08(SEQ ID NO:62),P00628_H02(SEQ ID NO:66),P00629_C08(SEQ ID NO:68),P00641_G11(SEQ ID NO:71),P00648_E12(SEQ ID NO:73),P00697_C03 ID NO:75)和其他哺乳动物 这些因子的同系物和变体,以及编码它们的多核苷酸。 本发明还涉及用于产生这些因素及其在诊断和治疗各种心脏,肾脏或炎症疾病中的用途的方法和手段。
摘要:
The invention pertains to isolated nucleic acid molecules containing sequences specified herein, to mutant CD36 genes and their encoded gene products, to methods of screening blood or a blood product by detecting a CD36 gene mutation, methods of administering blood or a blood product based on the presence or absence of a CD36 gene mutation, to methods of matching a biological sample donor with a recipient based on detection of a mutation in the CD36 gene, methods of determining the resistance of a patient to infection by a parasite by detecting a CD36 gene mutation, methods of diagnosing a disease associated with a defect in insulin action, glucose metabolism, fatty acid metabolism, and/or catecholamine action by detecting a mutation in the CD36 gene, and methods of disease treatment by altering the mutation(s).
摘要:
There is presently provided mutant Sox2, Sox7 and Sox17 proteins that have acquired or increased ability to induce pluripotency in a partially differentiated or fully differentiated cell. Sox7 and Sox17 are mutated to resemble in part Sox2, or Sox2 is mutated to resemble in part Sox7 or Sox17. In one aspect, the Oct4 contact interface of Sox7 or Sox17 is mutated. In another aspect, the high mobility group (HMG) of Sox2 is fused to the C-terminal activation domain of Sox7 or Sox17. Methods relating to inducing pluripotency using a mutant Sox2, Sox7 or Sox17 protein are also provided.
摘要:
The invention concerns new secreted factors encoded by clones P00184_D11 (SEQ ID NO:1), P00185_D11 (SEQ ID NO:3), P00188_D12 (SEQ ID NO:5), P00188_E01 (SEQ ID NO:7), P00194_G01 (SEQ ID NO:9), P00194_G05 (SEQ ID NO:11), P00194_H10 (SEQ ID NO:13), P00199_D08 (SEQ ID NO:15), P00203_D04 (SEQ ID NO:17), P00203_E06 (SEQ ID NO:19), P00209_F06 (SEQ ID NO:21), P00219_D02 (SEQ ID NO:23), P00219_F06 (SEQ ID NO:25), P00220_H05 (SEQ ID NO:27), P00222_G03 (SEQ ID NO:29), P00225_C01 (SEQ ID NO:32), P00227_D11 (SEQ ID NO:34), P00228_F03 (SEQ ID NO:36), P00233_H08 (SEQ ID NO:38), P00235_G08 (SEQ ID NO:40), P00239_C11 (SEQ ID NO:42), P00240_E05 (SEQ ID NO:45), P00247_A04 (SEQ ID NO:50), P00248_B04 (SEQ ID NO:52), P00249_F09 (SEQ ID NO:54), P00258_A10 (SEQ ID NO:56), P00262_C10 (SEQ ID NO:58), P00269_H08 (SEQ ID NO:62), P00628_H02 (SEQ ID NO:66), P00629_C08 (SEQ ID NO:68), P00641_G11 (SEQ ID NO:71), P00648_E12 (SEQ ID NO:73), P00697_C03 (SEQ ID NO:75), and other mammalian homologues and variants of such factor, as well as polynucleotides encoding them. The invention further concerns methods and means for producing such factors and their use in the diagnosis and treatment of various cardiac, renal or inflammatory diseases.
摘要翻译:本发明涉及由克隆P00184_D11(SEQ ID NO:1),P00185_D11(SEQ ID NO:3),P00188_D12(SEQ ID NO:5),P00188_E01(SEQ ID NO:7),P00194_G01(SEQ ID NO: P00194_G05(SEQ ID NO:11),P00194_H10(SEQ ID NO:13),P00199_D08(SEQ ID NO:15),P00203_D04(SEQ ID NO:17),P00203_E06(SEQ ID NO:19),P00209_F06 (SEQ ID NO:21),P00219_D02(SEQ ID NO:23),P00219_F06(SEQ ID NO:25),P00220_H05(SEQ ID NO:27),P00222_G03(SEQ ID NO:29),P00225_C01 P00227_D11(SEQ ID NO:34),P00228_F03(SEQ ID NO:36),P00233_H08(SEQ ID NO:38),P00235_G08(SEQ ID NO:40),P00239_C11(SEQ ID NO:42),P00240_E05 P00248_A04(SEQ ID NO:50),P00248_B04(SEQ ID NO:52),P00249_F09(SEQ ID NO:54),P00258_A10(SEQ ID NO:56),P00262_C10(SEQ ID NO: ),P00269_H08(SEQ ID NO:62),P00628_H02(SEQ ID NO:66),P00629_C08(SEQ ID NO:68),P00641_G11(SEQ ID NO:71),P00648_E12(SEQ ID NO:73),P00697_C03 SEQ ID NO:75)和其他哺乳动物同系物及其变体 因子,以及编码它们的多核苷酸。 本发明还涉及用于产生这些因素及其在诊断和治疗各种心脏,肾脏或炎症疾病中的用途的方法和手段。
摘要:
The invention concerns the use of agonists and antagonists of peripheral-type benzodiazcpine receptors (PTBR) in the diagnosis and treatment of cardiac hypertrophy and other circulatory conditions. The invention specifically concerns the use of PTBR antagonists in the prevention or treatment of decompensated cardiac hypertrophy and, eventually, heart failure. The invention also concerns the use of PTBR agonists in the management of conditions calling for increased blood flow or cardiac output, including injury or functional compromise of the heart, increased demand for physical exercise, or an acquired or inherited predisposition to cardiac contractile disfunction. Pharmaceutical compositions for the treatment of such conditions and screening methods to identify PTBR agonists and antagonists are also included.
摘要:
There is presently provided mutant Sox2, Sox7 and Sox17 proteins that have acquired or increased ability to induce pluripotency in a partially differentiated or fully differentiated cell. Sox7 and Sox17 are mutated to resemble in part Sox2, or Sox2 is mutated to resemble in part Sox7 or Sox17. In one aspect, the Oct4 contact interface of Sox7 or Sox17 is mutated. In another aspect, the high mobility group (HMG) of Sox2 is fused to the C-terminal activation domain of Sox7 or Sox17. Methods relating to inducing pluripotency using a mutant Sox2, Sox7 or Sox17 protein are also provided.
摘要:
The present invention relates to methods and compositions for the detection, diagnosis, prevention and treatment of a disease, specifically cardiac, kidney or inflammatory disease, and related disorders. The present invention also relates to compositions and methods useful in the diagnosis, prevention and therapeutic treatment of a disease, specifically cardiac, kidney or inflammatory disease. Specifically, methods and compositions are provided for the diagnostic evaluation and prognosis of conditions involving a disease, specifically cardiac, kidney or inflammatory disease, for the identification of subjects exhibiting a predisposition to such conditions, for modulating the effect of these differentially expressed genes, for monitoring patients undergoing clinical evaluation for the prevention and treatment of a disease, specifically cardiac, kidney or inflammatory disease, and its disorders, and for monitoring the efficacy of compounds used in clinical trials.